$15.49
+
$0.14 (0.91%)
End-of-day quote: 05/10/2024
ASX:TLX
Telix Pharmaceuticals Annual Report
| Year | Year | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Rev. | Revenue |
|
$502.55M | $160.10M | $7.60M | $5.21M | $3.49M | $0.20M | $0.00M | |
| GM % | Gross Margin % |
|
62.56% | 61.55% | 66.46% | 61.17% | 27.03% | 100.00% | 0.00% | |
| OM | Operating Margin |
|
10.32% | -45.71% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| EPS | Earnings Per Share |
|
$0.00 | $0.12 | $-0.28 | $-0.29 | $-0.17 | $-0.12 | $-0.07 | $-0.05 |
| Div. | Dividends |
|
$0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| PR % | Payout Ratio % |
|
0.00% | -0.00% | -0.00% | -0.00% | -0.00% | 0 | 0 | |
| Sha. | Shares |
|
323.73m | 316.34m | 285.07m | 280.41m | 253.28m | 218.37m | 197.44m | |
| OCF | Operating Cash Flow |
|
$23.88M | $-63.97M | $-59.33M | $1.96M | $-23.33M | $-20.75M | $-6.03M | |
| FCF | Free Cash Flow |
|
$47.63M | $-73.17M | $-62.05M | $1.71M | $-23.73M | $0.00M | $-6.04M | |
| FCFS | Free Cash Flow Per Share |
|
$0.04 | $-0.25 | $-0.21 | $0.01 | $-0.10 | $-0.10 | $-0.05 |
